Results 101 to 110 of about 1,753 (162)

Letter: Lebrikizumab for Refractory Atopic Dermatitis

Dermatitis®
Natalia V, Chalupczak, Peter, Lio
openaire   +2 more sources

Correction: Retrospective Analysis of Lebrikizumab in the Management of Atopic Dermatitis: Insights from Real-World Practice. [PDF]

Dermatol Ther (Heidelb)
Stavropoulos N, Myszkowski D, Braß D, Dervenis V, Poungoura E, Stockfleth E.   +5 more
europepmc   +1 more source

Benign familial pemphigus treated with lebrikizumab

JAAD Case Reports
Harisankeerth Mummareddy, Nagasai C. Adusumilli, Adam J. Friedman, Christina Tolete, Joseph Zahn, Leonardo Tjahjono   +5 more
openaire   +1 more source

Letter to the Editor Regarding "Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo Adjusted Indirect Treatment Comparison". [PDF]

Dermatol Ther (Heidelb)
Chovatiya R, Seminario-Vidal L, Gallo G, Ding Y, Yang C, Akmaz B, Solé-Feu L, Rand K.   +7 more
europepmc   +1 more source

Lebrikizumab para el tratamiento de la dermatitis atópica

El medicamento Ebglyss® (lebrikizumab-lbkz) recibe el visto bueno tanto de la EMA como de la FDA para tratar los casos de dermatitis atópica de moderada a severa en adultos y adolescentes mayores de 12 años que no remita con otros tratamientos ...
Ruiz-Conca, Mateo
core  

Biologic Monotherapies for Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Bayesian Network Meta-Analysis of Established and Investigational Agents. [PDF]

Cureus
Babul A, Mehta D, Soliman Y, Hussain M, Babul N.   +4 more
europepmc   +1 more source

Lebrikizumab is Efficacious in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis Regardless of Atopic Comorbidities

Background Atopic comorbidities are common in patients with atopic dermatitis (AD) and increase disease burden. Lebrikizumab monotherapy demonstrated efficacy and safety through 52 weeks in patients with moderate-to-severe AD in phase 3 trials (ADvocate1
de Bruin-Weller, Marjolein, Zhong, Jinglin, Bieber, Thomas, Boguniewicz, Mark, Mehta, Vinay, Infection & Immunity, Atwater, Amber Reck, MS Dermatologie/Allergologie, Sher, Ellen R, Golant, Alexandra, Dawson, Zach, Calleja, Lidia Rodriguez, Carrascosa, Jose-Manuel   +12 more
core  

Comparing the Efficacy and Safety of Nemolizumab Versus Anti-interleukin Monoclonal Antibody Therapies in Combination with Topical Treatments for Moderate-to-Severe Atopic Dermatitis Using Network Meta-analysis. [PDF]

Dermatol Ther (Heidelb)
Pink AE, Houghton J, White H, Schiavo S, Piketty C, Ulianov L, Rout R, Jack K, Subramanian R, Puelles J.   +9 more
europepmc   +1 more source

A Response to "Letter to the Editor Regarding 'Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison'". [PDF]

Dermatol Ther (Heidelb)
Ständer S, Pinter A, Hougeir FG, Guyot P, Xu Y, Praestgaard AH, Freemantle N, Rossi AB, Bégo-Le-Bagousse G, Wang Z, Noonan K, Bastian M.   +11 more
europepmc   +1 more source

Comparative efficacy and safety of biologic therapies in pediatric asthma: a comprehensive systematic review. [PDF]

Front Med (Lausanne)
Alzayed A.
europepmc   +1 more source